Gainers

• IceCure Medical Ltd ICCM +0.35% rose 36.5% to $3.89 in pre-market trading. IceCure Medical, last week, received notice of intention to grant a European patent covering its cryogenic pump.
• American Virtual Cloud Technologies, Inc. AVCT +0% rose 25.8% to $2.39 in pre-market trading after dipping 24% on Thursday.
• RISE Education Cayman Ltd REDU +0% rose 15.3% to $0.6106 in pre-market trading following a 5% surge on Thursday.
• Genocea Biosciences, Inc. GNCA +0% shares rose 12.5% to $1.40 in pre-market trading after gaining around 20% on Thursday.
• Aridis Pharmaceuticals, Inc. ARDS +0% rose 9.8% to $2.90 in pre-market trading. Aridis Pharmaceuticals, last week, announced its fully human monoclonal antibody cocktail AR-701 is broadly reactive against the Omicron and other COVID-19 variants, SARS, MERS and the common cold coronaviruses.
• Orbsat Corp. OSAT +0.54%  rose 8.4% to $4.01 in pre-market trading after dropping over 5% on Thursday. The company, last month, reported Q3 sales of $2.25 million.
• Nxt-ID, Inc. NXTD +0% rose 7% to $4.29 in pre-market trading after surging around 20% on Thursday.
• Inspira Technologies Oxy B.H.N. Ltd. IINN +0%
   rose 6% to $3.88 in pre-market trading after tumbling 12% on Thursday.
• XpresSpa Group, Inc. XSPA +0%  rose 5.5% to $2.11 in pre-market trading.
• Gevo, Inc. GEVO +0% shares rose 5.4% to $5.10 in pre-market trading.

Image Source: Unsplash

Losers

• BiondVax Pharmaceuticals Ltd. BVXV +0% fell 15.1% to $2.36 in pre-market trading after the company reported a proposed underwritten public offering of American Depositary Shares.
• Snow Lake Resources Ltd. LITM +0% shares fell 5.9% to $5.46 in pre-market trading after dropping over 3% on Thursday.
• Genfit SA GNFT +0% fell 5.9% to $5.08 in pre-market trading. Genfit and Ipsen recently announced an exclusive licensing agreement for elafibranor.
• Sonnet BioTherapeutics Holdings, Inc. SONN +0% shares fell 5.2% to $0.43 in pre-market trading. Chardan Capital, last week, maintained Sonnet BioTherapeutics with a Buy and lowered the price target from $8 to $2.5.
• Ensysce Biosciences, Inc. ENSC +0% shares fell 4.3% to $4.90 in pre-market trading. Ensysce Biosciences recently said that the first patients have been enrolled in Phase 1 study of PF614-MPAR, its unique technology platform to provide opioid overdose protection.